Vol 14, No 1 (2011)
Research paper
Published online: 2011-07-12
The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours
Nucl. Med. Rev 2011;14(1):16-20.
Abstract
BACKGROUND: Positron emission tomography (PET) combined
with computer tomography (CT) using 68Ga-DOTATATE
is a promising method for the evaluation of patients with recognised
or suspected neuroendocrine tumours (NET). The aim of
this study was to assess the diagnostic value of 68Ga-DOTATATE
PET/CT in the visualisation of the expression of somatostatin
receptors (SSTR) and identification of new lesions.
MATERIAL AND METHODS: Between December 2009 and January 2011 ninety-seven patients with confirmed (88 cases) or suspected (9 cases) NET underwent 68Ga DOTATATE PET/CT. The primary, confirmed or suspected, NET localizations were: GEP tumours — 71 patients; medullary thyroid carcinoma — 4 patients; cancer of an unknown primary — 14 patients; and NET in other localisations — 8 patients. PET/CT acquisitions were performed using standard techniques, 45 to 60 minutes after the intravenous injection of 111–185 MBq 68Ga-DOTATATE.
RESULTS: 68Ga-DOTATATE PET/CT detected the presence of lesions demonstrating the somatostatin receptor affinity in 50 of the 97 patients (51.5%) and was negative in 47 patients (48.5%). Among 14 patients with metastatic unknown primary cancer, in 5 patients (45.5%) the primary tumour site was identified, and in 4 patients with medullary thyroid cancer distant metastases with SSTR expression were localized in only one patient.
CONCLUSIONS: Our findings confirm the diagnostic role of 68Ga-DOTATATE PET/CT as an accurate method of identifying primary tumours and distant metastases. It provides information on tumour cell receptors status, which has a significant bearing on planning target radionuclide therapy. Overall, 68Ga-DOTATATE PET/CT can be used in staging, re-staging, and in regular follow up of oncology patients.
Nuclear Med Rev 2011; 14, 1: 16–20
MATERIAL AND METHODS: Between December 2009 and January 2011 ninety-seven patients with confirmed (88 cases) or suspected (9 cases) NET underwent 68Ga DOTATATE PET/CT. The primary, confirmed or suspected, NET localizations were: GEP tumours — 71 patients; medullary thyroid carcinoma — 4 patients; cancer of an unknown primary — 14 patients; and NET in other localisations — 8 patients. PET/CT acquisitions were performed using standard techniques, 45 to 60 minutes after the intravenous injection of 111–185 MBq 68Ga-DOTATATE.
RESULTS: 68Ga-DOTATATE PET/CT detected the presence of lesions demonstrating the somatostatin receptor affinity in 50 of the 97 patients (51.5%) and was negative in 47 patients (48.5%). Among 14 patients with metastatic unknown primary cancer, in 5 patients (45.5%) the primary tumour site was identified, and in 4 patients with medullary thyroid cancer distant metastases with SSTR expression were localized in only one patient.
CONCLUSIONS: Our findings confirm the diagnostic role of 68Ga-DOTATATE PET/CT as an accurate method of identifying primary tumours and distant metastases. It provides information on tumour cell receptors status, which has a significant bearing on planning target radionuclide therapy. Overall, 68Ga-DOTATATE PET/CT can be used in staging, re-staging, and in regular follow up of oncology patients.
Nuclear Med Rev 2011; 14, 1: 16–20
Keywords: 68Ga-DOTATATEPET/CTneuroendocrine tumours
